IGF-1 LR3: A Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
- IGF-1 LR3 is a lab-made (engineered) version of a natural growth signal called insulin-like growth factor 1, changed so it lasts longer and is mostly used as a chemical tool in cell-culture experiments.
- What the research actually shows is narrow: published studies are limited to cells in dishes and animals, used to study how the IGF-1 receptor and cell growth pathways work, and those results do not carry over to people.
- Honest on evidence strength: there are essentially no human trials of IGF-1 LR3 itself, and the muscle-and-recovery claims seen on fitness and biohacker forums are unverified personal reports, not controlled data.
- It is not approved: no FDA or other human approval exists for IGF-1 LR3, and as a growth factor it is banned in sport at all times under the World Anti-Doping Agency list.
- BioRegen sells IGF-1 LR3 strictly for laboratory and educational research, not for use in humans or animals, and makes no claims that it works.
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. IGF-1 LR3 (also called Long R3 IGF-1) is a lab-made version of a natural growth signal called insulin-like growth factor 1 (IGF-1). Scientists study it in cell samples and animal models to learn how cells grow and multiply.
What IGF-1 LR3 Is
IGF-1 LR3 is a lab-built copy of the natural IGF-1 protein, but with two small changes to its building blocks. One change swaps a single piece (an amino acid) near the start of the chain. The other adds a short extra tail of 13 building blocks to one end. In published research, these two changes are described as making the molecule stick much less to a group of carrier proteins in the body called IGF-binding proteins, while it still latches onto the cell's main IGF docking point (the type 1 IGF receptor). Because of this, scientists use it in the lab to study how that docking point sends signals, without the carrier proteins getting in the way.
Mechanism and What Research Explores
Because it barely sticks to the carrier proteins but still binds the cell's IGF docking point, studies have used it as a tool to watch what happens when that docking point is switched on, and how that signal tells cells to grow and multiply. In some research, scientists used it in muscle-cell samples to tell apart two things: effects that come from the IGF signal itself, and effects that come from the carrier proteins. It has also been used as a steady, long-lasting form of IGF-1 in early animal studies of blood vessels. The main interest is in learning how a steady "on" signal at this docking point affects whether cells grow, change into new cell types, or stay alive, all under controlled conditions in the lab dish.
Research Stage and Limitations
Almost all of the research on IGF-1 LR3 has been done in cell samples in a dish or in animals. Results from that kind of work do not carry over directly to people or pets, and this compound is not approved for use in either. The results also change a lot depending on which cells are used, how the test is set up, and which carrier proteins are present, so it is hard to draw broad conclusions. Any mention of IGF-1 LR3 outside of controlled research, such as personal stories shared online, should be treated as unproven anecdotes, not solid findings. BioRegen does not make or back any claims based on them.
Laboratory Handling Notes
Like many research peptides and proteins, IGF-1 LR3 usually comes as a freeze-dried powder. In the lab, researchers mix it back into liquid with a suitable fluid before they work with it. As a general lab habit, researchers try not to freeze and thaw it over and over, keep the mixed liquid cold, and write down the batch number and storage details so the work can be repeated. For background on how peptides are mixed back into liquid in a research setting, see our guide on how to reconstitute peptides. Researchers comparing growth-research compounds may also find the growth research category useful for looking over the available reference materials.
Is IGF-1 LR3 the same as native IGF-1?
No. In research, it is described as a lab-made version with two changes: one swapped building block near the start and a short extra tail on one end. Research says these changes make it stick less to the carrier proteins than the natural molecule does, while it still binds the cell's docking point.
Why do researchers use the LR3 form in cell culture?
Studies have used it because it sticks so little to the carrier proteins. That lets researchers study the signal at the cell's IGF docking point with less interference from the carrier proteins floating in the cell-growth liquid.
How does it compare to other growth-research compounds?
It depends entirely on the research question and the model being used. To look over and compare reference compounds, researchers can use our research finder.
For Research Teams
For background on how to source and keep records for lab reference materials, see the BioRegen research guide, and create a free account for 10% off your first order. You can also browse the growth research category to compare available reference compounds.
Selected research references
- von der Thüsen JH, et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am J Pathol. 2011. https://doi.org/10.1016/j.ajpath.2010.10.007
- Xi G, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol. 2004. https://doi.org/10.1002/jcp.20068
Reference metadata sourced via PubMed.
This article is provided for laboratory and educational research purposes only. No compound referenced is approved for human or veterinary use, and nothing here constitutes medical advice or a recommendation for use in humans or animals. BioRegen does not make therapeutic claims.